Skip to main content
. 2008 Sep 19;10(5):R78. doi: 10.1186/bcr2145

Table 5.

Hazard ratios of dying from breast cancer in relation to use of menopausal hormone therapy

Breast cancer deaths/exposed (n) Mortality ratea Hazard ratio (95% confidence interval)b Hazard ratio (95% confidence interval)c
Never use 230/1,491 1.9 1.0 (reference) 1.0 (reference)
Current used 46/477 1.1 0.55 (0.40 to 0.77) 0.63 (0.42 to 0.95)
 By duration
  <5 years 28/216 1.5 0.73 (0.48 to 1.13) 0.76 (0.45 to 1.27)
  ≥ 5 years 18/260 0.8 0.42 (0.26 to 0.68) 0.52 (0.29 to 0.93)
 By regimen
  Estrogen-progestin 37/391 1.1 0.54 (0.37 to 0.77) 0.59 (0.38 to 0.91)
  Estrogen alone 8/80 1.1 0.59 (0.29 to 1.20) 0.78 (0.34 to 1.80)
Past usee 34/219 1.9 1.01 (0.71 to 1.45) 1.03 (0.68 to 1.54)
 By duration
  <5 years 25/155 1.9 1.04 (0.69 to 1.58) 1.02 (0.64 to 1.63)
  ≥ 5 years 9/64 1.7 0.94 (0.48 to 1.83) 1.02 (0.48 to 2.17)

Observations with missing information on menopausal hormone therapy, recent mammography, tumor size, or lymph node involvement excluded. aBreast cancer deaths per 100 person-years. bAdjusted for age at diagnosis (5-year categories), recent mammography (yes/no). cAdjusted for age at diagnosis (5-year categories), recent mammography (yes/no), adjuvant endocrine therapy (yes/no) and adjuvant chemotherapy (yes/no), tumor size, and lymph node involvement. dLast use <6 months before diagnosis. eLast use at least 6 months before diagnosis.